Document Detail

The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
MedLine Citation:
PMID:  23195008     Owner:  NLM     Status:  In-Data-Review    
Antibody-mediated rejection (AMR) typically occurs early after transplantation in approximately 5%-7% of recipients. The literature reports suggest that 12%-37% of kidney transplant recipients with acute AMR do not respond to treatment and eventually lose their grafts. The proteasome inhibitor bortezomib is currently approved by the Food and Drug Administration for the treatment of multiple myeloma. It has been demonstrated both in vitro and in vivo to possess apoptotic properties against mature plasma cells. Herein we have described a series of 3 patients with positive cross-matches who developed early AMR after kidney transplantation. Bortezomib rescue treatment was administered after the patients failed to respond to plasmapheresis/intravenous immunoglobulin and splenectomy. All 3 patients responded with full, durable recovery of renal function. In conclusion, bortezomib is useful to treat refractory AMR after kidney transplantation.
I Tzvetanov; M Spaggiari; J Joseph; H Jeon; J Thielke; J Oberholzer; E Benedetti
Related Documents :
11548 - Fetal thymus transplantations in severe combined immunodeficiency.
23432918 - Acute pancreas allograft rejection is associated with increased risk of graft failure i...
24070588 - Morbid obesity is not an independent predictor of graft failure or patient mortality af...
20353468 - Molecular markers and targeted therapy of skin rejection in composite tissue allotransp...
9002298 - Pathological improvement of iga nephropathy and henoch-schönlein purpura nephritis wit...
22401278 - Follicle development in cryopreserved bitch ovarian tissue grafted to immunodeficient m...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Transplantation proceedings     Volume:  44     ISSN:  1873-2623     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2971-5     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Division of Transplantation, Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Next Document:  Ten years of renal transplantation in a moroccan hospital: results and constraints.